Pith. sign in

REVIEW 1 cited by

TransDiffSBDD: Causality-Aware Multi-Modal Structure-Based Drug Design

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2503.20913 v1 pith:VTQ2CH7L submitted 2025-03-26 cs.CE cs.LG

classification cs.CEcs.LG
keywords designdrugmodalitiesmolecularsbddtransdiffsbddaddressautoregressive
verification ladder T0 review T1 audit T2 compute T3 formal
0 comments
read the original abstract

Structure-based drug design (SBDD) is a critical task in drug discovery, requiring the generation of molecular information across two distinct modalities: discrete molecular graphs and continuous 3D coordinates. However, existing SBDD methods often overlook two key challenges: (1) the multi-modal nature of this task and (2) the causal relationship between these modalities, limiting their plausibility and performance. To address both challenges, we propose TransDiffSBDD, an integrated framework combining autoregressive transformers and diffusion models for SBDD. Specifically, the autoregressive transformer models discrete molecular information, while the diffusion model samples continuous distributions, effectively resolving the first challenge. To address the second challenge, we design a hybrid-modal sequence for protein-ligand complexes that explicitly respects the causality between modalities. Experiments on the CrossDocked2020 benchmark demonstrate that TransDiffSBDD outperforms existing baselines.

Discussion (0). Continue with ORCID to comment.

Forward citations

Cited by 1 Pith paper

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

  1. Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy

    cs.AI 2025-07 unverdicted novelty 2.0 of 10

    A literature review of AI/ML in drug discovery, with a case study summarizing network pharmacology and machine learning based target and hit discoveries for gout-related diseases.

Pith tools